The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.

We have aimed to investigate the relationship between use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin-receptor-blocker (ARB) drugs and acute hypoxemic respiratory failure (AHRF) and in-hospital mortality in hypertensive Covid-19 patients. Consecutive 1345 patients diagnosed with Covid-19 between April and October 2020 who met inclusion criteria were divided into two groups based on presence and absence of AHRF and mortality. The groups were compared regarding epidemiological, clinical, radiological, laboratory findings and treatments methods. The patient groups ACEI, ARB and other antihypertensive drugs (non-ACEI/ARB) were compared regarding same parameters. Median age was 68 (60–76) years in the patient group including 805 (59.9.1%) females. Of the patients, 475 (35.3%), 644 (47.9%) and 226 (16.8%) were using ACEIs, ARBs and non-ACEI/ARB, respectively. AHRF and in-hospital mortality developed in 1053 (78.3%) and 290 (21.6%) patients, respectively. Age, gender, coronary artery disease, diabetes mellitus (DM), neutrophil, lymphocyte, creatinine, D-dimer, C-reactive protein (CRP), ACEI, beta blocker and aspartate transaminase (AST) found statistically significant in the univariable logistic regression performed to identify independent predictors of mortality were included multivariable logistic regression model. Age (OR: 1.066, 95%CI: 1.049–1.083; p <.001), DM (OR: 1.682, 95%CI: 1.238–2.286; p =.001), neutrophil (OR: 1.041, 95%CI: 1.007–1.077; p =.019), creatinine (OR: 1.178, 95%CI: 1.048–1.325; p =.006), CRP (OR: 1.008, 95%CI: 1.006–1.010; p <.001), ACEI (OR: 0.718, 95%CI: 0.521–0.988; p =.042), AST (OR: 1.005, 95%CI: 1.001–1.010; p =.010) were found associated with in-hospital mortality. In our study, it was not detected clinically significant difference between three groups with regard to their relation with in-hospital mortality. [ABSTRACT FROM AUTHOR]